Insulin Use With Metformin | Diabetic Connect
I have type 2 diabetes and had a neighbor tell me that metformin is on the 'bad drug list" in combination with insulin. That it can increase mortality, cardiovascular and and kidney problems. His doctor took him off metformin because of this. I have googled this and find there are warnings out there for this but nothing really conclusive over a long period of time. Has anyone heard about this? My doctor took me off all pills in that they do nothing for me Did all the different types since finding out I was diabetic 11 years ago Pancreas is no longer producing insulin . So just on insulin now . First Lantus & Novolog using pens but now on pump and just using Novolog There is a very informative web site called mediguard.org. Once you registrar you list all the drugs you take. The will send you an email listing all the adverse side effects of each drug and how they interact with each other. I am on 2000 mg of metformin and lantus solostar insulin. The only thing they warn about taking the two is metformin might increase ones sensitivity to insulin increasing the risk of hypoglycemia. I have been using the two together for about 14 months with great results and with out any problems One of our DC members brought my attention to mediguard.org and it has been a tremendous help to me in answering any questions about the meds I'm taking Continue reading >>
Adding Lantus To Metformin And Glimiperide
Adding Lantus to Metformin and Glimiperide Adding Lantus to Metformin and Glimiperide 60, female, Type 2. Until recently, I have managed my diabetes with Metformin and Byetta. I took Glimiperide as well for awhile, starting with 4 mg twice a day. The Glimiperide caused me to crash every day, so we kept decreasing the dosage trying to stop the crashes. I could never stop the crashes, so I discontinued it. The Byetta always made me nauseous, which I hated but tolerated. However, it can also make me vomit, which seems to have increased, and that I cannot tolerate. So, I stopped taking Byetta, and I am now on Metformin and Glimiperide again. Even without the Byetta, the Glimiperide has caused a crash three times in the last week. Now my doctor wants me to go on 20 units of Lantus at bedtime, WITH the Glimiperide. I am very nervous about this. If I'm already crashing without the Lantus, what will happen when I'm taking it too? I can only tell you what I would do and that is to ditch the Glimperide and go on the Lantus however I would not start out with 20 units. Share what your sugars run if you are comfortable doing so. Welcome to DD. D.D. Family Getting much harder to control Hi and welcome to DD as Dusty stated I would ditch the Glimerpride and do the Lantus if your going low each day on it that shows your pancreas is still producing lots of insulin. Have you cut your carbs because with some tweaking you might be able to do just the metformin but without info its hard to say. My blood sugars are all over the place. Yesterday I had a reading of over 300 after eating raisin bran for breakfast. That's what's frustrating - I have highs and then lows. My morning reading, before breakfast, is usually 150-180. I've had the crashes at 11 in the morning and right before dinner. M Continue reading >>
Lantus Solostar - Does Anyone Take An Oral Diabetes Medication Along With Lantus?
Home Q & A Questions Lantus Solostar - Does anyone... Lantus Solostar - Does anyone take an oral diabetes medication along with lantus? Your dr isn't going to start you on more then he thinks your blood sugar can stand. You're going to be taking glucose levels and watching it. Keep juice and some protein like cheese or peanut butter availabel and you'll be ok. I take Lantus Solostar & Metformin together & as long as you are checking your blood sugars you should be fine. If you are un-easy about low blood sugar just watch for signs & check your blood sugars more often. Obviously your Dr. feels you need this adjustment to control your diabetes. Just make sure you carry your meter & some type of protein with you at all times. you should be fine. I too take 50 units at night its a long acting insulin and I take novalog sliding scale five times a day. just be sure to check it and I normally eat a healthy snack after I take it to make sure it doesn't drop too low. I learned that from a hospital stay. I started Lantus (8 units at bedtime) 2 months ago and still take Diamicron MR every morning. I've had no problems with low blood sugar and I'm hitting my targets now. I used to have a problem controlling sugar overnight, but not anymore. I was really nervous, too but I'm sure you'll be fine. BTW - Does anyone else have trouble sleeping while on Lantus medication? I seem to fall asleep without trouble but am awake 2 hours later for most of the night. Having some strange (not scary) dreams, too! I started Lantus SoloStar two weeks ago and it's working well, I think. I take metformin, diamicron mr and Januvia, all diabetes meds. The diabetic counselor at the hospital said the pills will likely be adjusted as my numbers come down and I stabilize. I hope I can stop taking some of th Continue reading >>
Insulin With Actos, Prandin And Metformin
Insulin with Actos, Prandin and Metformin Registration is fast, simple and absolutely free so please,join our community todayto contribute and support the site. This topic is now archived and is closed to further replies. Insulin with Actos, Prandin and Metformin My first post so apologies if questions below have already been answered I was diagnosed in 2004 as a diabetic and since then, until June of this year was on various medications with high fasting and high PP sugar. A1C ranged from 6 to 9 over the years and in the last year, it was continually edging up despite (1) increasing doses of Actos, Prandin, Metformin and Glipizide, (2) managing diet, and (3) exercising. So, finally, got on to Lantus Solostar insulin (inject once a day in the late evening) - right now at 30 units and also take Actos 45, Prandin 2MG (x3) and Metformin 1000 (x2). The question I have is: Which of these medicines are necessary or helpful to have along with Insulin? Which ones can I try to eliminate? TIA. Just an update: I have eliminated Actos without any significant impact (as far as I can tell). Currently at 40 units of Lantus Solostar + 2mg Prandin twice a day + 1000mg Metformin twice a day. Blood Glucose 120 today but I am still not at a stable level so may have to increase Insulin. Welcome Mahendra. That's quite a list of meds, no wonder you would prefer to be off some of them, and insulin seems like the best choice for you. We do discuss various meds on this forum, but with few exceptions this are our personal opinions, not based on any medical training, so it is probably not the best source on information for such questions. Having said that, here is my opinion- worth what you paid for it. I would think you could eliminate all these drugs with the possible exception of metformin. Me Continue reading >>
- NZ case study; A citizen scientist controls autoimmune diabetes without insulin, with a low carb diet, a glucose meter, and metformin.
- Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
Lantus Solostar And Metformin Drug Interactions - Drugs.com
Do not stop taking any medications without consulting your healthcare provider. Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. Some mixtures of medications can lead to serious and even fatal consequences. Continue reading >>
Adding Lantus To Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar In Patients With Type 2 Diabetes - Sep 20, 2010
Adding Lantus to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes - Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting - PARIS, Sept. 20 / PRNewswire-FirstCall / -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy (OADs), was associated with a greater reduction in A1C levels and lower incidence of any hypoglycemia versus all comparators (OADs, NPH, lispro, premix). In the second pooled analysis of clinical studies, "patients with type 2 diabetes, who used Lantus as monotherapy or added it to one baseline oral antidiabetic agent, demonstrated a greater reduction in A1C with lower risk of hypoglycemia than those taking two OADs, with a most significant reduction when Lantus was added to metformin alone versus other OADs [sulfonylurea alone or sulfonylurea plus metformin]," said Dr. Jack Leahy of the University of Vermont College of Medicine and principal investigator of one of the studies. Better Efficacy and Goal Attainment Demonstrated with Insulin Glargine versus All Comparators(1) "Efficacy and Goal Attainment with Insulin Glargine vs Comparators" [presentation number 976]: This pooled analysis looked at nine clinical studies where insulin-nave patients with type 2 diabetes uncontrolled on OADs were randomized to add Lantus (n=1,462) or comparators (OADs, NPH, lispro or premix; n=1,476) to their treatment re Continue reading >>
Compare Metformin Vs. Lantus
Lowers blood sugar. Glucophage (metformin) is the first choice medicine to control your blood sugar and lower the risk of death from diabetes, although a few people may not tolerate the stomach side effects. Improves sugar control and lowers A1c levels as much as 2%. One of the few diabetes medicines that lowers the risk of death from diabetes-related complications. Rarely causes low blood sugar. Insulin is one of the most effective blood sugar-lowering medication and can lower your A1c (average blood sugar over time) by up to 2-3%. Lantus (insulin glargine) is a long-lasting insulin that provides consistent, all-day sugar control with just once or twice daily dosing. Dose can be easily adjusted to make a customized regimen that's tailored to your body's needs. Lantus (insulin glargine) can be used with liver or kidney problems. 938 reviews so far Have you used Glucophage (metformin)? Leave a review 584 reviews so far Have you used Lantus (insulin glargine)? Leave a review Continue reading >>
Lantus (insulin Glargine)
Tweet Lantus is an analogue insulin produced by Sanofi-Aventis with the medical name insulin glargine. Lantus has been available for pharmaceutical use since the year 2000. Lantus hit the news in June 2009 over concerns that it may lead to the formation of cancer. However, the European Medicines Agency (EMEA) found the evidence suggesting the link to be inconclusive and cleared the drug for further use. What is Lantus? Lantus is an ultralente (long acting) analogue insulin. The medical name for Lantus, insulin glargine, is taken from how the DNA of human insulin is modified to form the analogue. In glargine’s case, glycine and two arginines are part of the genetic recombination that helps to produce the insulin. Who is Lantus prescribed to? Lantus can be prescribed for all types of diabetes. However, it is most commonly prescribed to people with type 1 diabetes. Lantus may be prescribed to people with type 2 diabetes for whom oral hypoglycemic agents have not shown to be sufficiently effective. How do I take Lantus? Lantus is injected, usually once daily at the same time each day. Like all insulins, Lantus should be injected subcutaneously (into the fatty tissue underneath the skin). The specific mode of action of Lantus means that it should never be diluted or mixed with any other insulin before injecting. Benefits of Lantus The mode of action of Lantus allows for a peakless profile. Lantus has become a popularly prescribed insulin as its consistent activity can help to reduce nocturnal hypoglycaemia. Side effects of Lantus Being an insulin, hypoglycemia can be a relatively common side effect of using Lantus, if dosages are too strong. Other side effects include allergic reactions and swelling, itching or pain at the injection site. Lantus and cancer link In June 200 Continue reading >>
Ep2785366a1 - Insulin Glargine Versus Metformin For The First-line Treatment Of Early Type 2 Diabetes - Google Patents
EP2785366A1 - Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes - Google Patents Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes EP2785366A1 EP20120799541 EP12799541A EP2785366A1 EP 2785366 A1 EP2785366 A1 EP 2785366A1 EP 20120799541 EP20120799541 EP 20120799541 EP 12799541 A EP12799541 A EP 12799541A EP 2785366 A1 EP2785366 A1 EP 2785366A1 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K38/00Medicinal preparations containing peptides A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans The invention relates to a method for treating type 2 diabetes patients, wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective, wherein the type 2 diabetes is early type 2 diabetes, more particularly, wherein the insulin glargine is used as first-line drug. Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes The invention relate
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial
- Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes
New Metformin Combination Medicine Approved For Type 2 Diabetes
On October 30, the US Food and Drug Administration (FDA) approved the combination oral diabetes drug Xigduo XR for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. The medicine, a development of AstraZeneca, combines dapagliflozin (brand name Farxiga), an SGLT2 inhibitor, and extended-release metformin (Glucophage XR and others). In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main proteins responsible for this reabsorption is SGLT2. By inhibiting the action of SGLT2, Farxiga blocks the reabsorption of glucose by the kidneys, promoting a loss of glucose in the urine and lowering blood glucose levels. Metformin works by decreasing the amount of glucose made by the liver and by improving insulin sensitivity in the liver, muscle, and fat cells. Xigduo XR, the first once-daily combination tablet of an SGLT2 inhibitor and extended-release metformin approved in the United States, will be offered in doses of 5 milligrams of dapagliflozin/500 milligrams of metformin, 5 milligrams of dapagliflozin/1,000 milligrams of metformin, 10 milligrams of dapagliflozin/500 milligrams of metformin, and 10 milligrams of dapagliflozin/1,000 milligrams of metformin to be taken once a day in the morning with food. This medicine should not be used in people with Type 1 diabetes, diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body), or moderate to severe kidney impairment. Because of the inclusion of metformin, Xigduo XR carries the risk of a rare but serious metabolic complication known as lactic acidosis. The most commonly reported side effects of Farxiga plus metformin compared to placebo (inactive treatment) plus metfo Continue reading >>
Lantus Solostar And Metformin Drug Interactions - From Fda Reports - Ehealthme
Lantus solostar and Metformin drug interactions - from FDA reports Drug interactions are reported among people who take Lantus solostar and Metformin together. This review analyzes the effectiveness and drug interactions between Lantus solostar and Metformin. It is created by eHealthMe based on reports of 1,076 people who take the same drugs from FDA , and is updated regularly. On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our original studies have been referenced on 400+ peer-reviewed medical publications, including: The Lancet, and Mayo Clinic Proceedings. 1,076 people who take Lantus solostar, Metformin are studied. Most common drug interactions over time *: Hypoglycaemia (deficiency of glucose in the bloodstream) Malaise (a feeling of general discomfort or uneasiness) Nausea (feeling of having an urge to vomit) Hyperkalaemia (damage to or disease of the kidney) Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture) Hypoglycaemia (deficiency of glucose in the bloodstream) Abortion spontaneous (naturally occurring miscarriage) Hypoglycaemia (deficiency of glucose in the bloodstream) Mitral valve disease (disease of mitral valve of heart) Hypoglycaemia (deficiency of glucose in the bloodstream) Most common drug interactions by gender *: Hypoglycaemia (deficiency of glucose in the bloodstream) Malaise (a feeling of general discomfort or uneasiness) Injection site haemorrhage (bleeding from injection site) Malaise (a feeling of general discomfort or uneasiness) Hypoglycaemia (deficiency of glucose in the bloodstream) Abortion spontaneous (naturally occurring miscarriage) Hypoglycaemia (deficiency o Continue reading >>
Triple Combination Of Insulin Glargine, Sitagliptin And Metformin In Type 2 Diabetes: The Easie Post-hoc Analysis And Extension Trial
Abstract We examined the effects of adding glargine to metformin–sitagliptin (MS + G) or sitagliptin to metformin–glargine (MG + S) therapy in type 2 diabetic persons uncontrolled after 24-week MS or MG dual therapy. Subjects with A1c ≥ 7% on MS or MG treatment were respectively given glargine (0.2 U/kg starting dose) or sitagliptin (100 mg daily) for 12 weeks. The primary endpoint was number of subjects attaining A1c goal defined as < 7%. After receiving 24-week MS or MG dual therapy in the original EASIE Study, 42% (104/248) on MS and 68% (152/224) on MG attained A1c < 7% (p < 0.0001). The reduction in A1c was negatively associated with baseline fasting blood glucose (FBG) only in the MG group. Reduction in A1c was not related to baseline postprandial blood glucose (PPBG) in either the MG or MS group. Amongst 194 eligible patients, 57.7% (n = 111) entered the 12-week extension trial [MS + G:74/131, 57.3%; MG + S:37/63, 58.7%) with 55 (51.9%) subjects attaining goal [MS + G:59.2%; MG + S:37.1%] at week 12. The final insulin dosage was similar in both groups [MS + G: 0.46 U/kg; MG + S: 0.45 U/kg] with a higher rate of hypoglycemia in the MG + S (6.5 events/patient-year) than the MS + G group (3.2 events/patient-year), although neither group had severe hypoglycemia. In metformin-treated type 2 diabetes patients, high fasting BG predicted greater A1c reductions with the addition of glargine, but not with sitagliptin. In subjects uncontrolled with 6-month dual therapy of MS or MG, 50% attained A1c < 7% with triple therapy of MS + G or MG + S in 12 weeks. The increased rate of hypoglycemia with MG + S (but not with MS + G) underlines the need to take measures to avoid the hypoglycemia. Conflict of Interest: J.C.N. Chan, P. Aschner, D.R. Owens, M. Vincent, M-P. Dain, V Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
- Type 1 diabetes trial patient insulin-free after treatment
Lilly Fortifies Its Trulicity Case With New Lantus-beating Combo Data
Eli Lilly & Co. rolled out its weekly GLP-1 drug Trulicity in late 2014, looking to challenge Novo Nordisk’s ($NVO) daily Victoza, which had dominated that market for years. But Lilly ($LLY) hasn’t been resting on its weekly dosing alone. After all, it’s also up against GlaxoSmithKline’s ($GSK) Tanzeum and AstraZeneca’s ($AZN) Bydureon, both dosed at the same frequency. It’s been racking up new Trulicity data in a variety of patient groups to build a broader case for the med. Case in point: The AWARD-9 trial presented on Sunday at the American Diabetes Association’s Scientific Sessions. The study tested Trulicity alongside Sanofi’s (4SNY) Lantus (insulin glargine), and the combo beat Lantus alone at every measure. The new data is important “because it adds to the dataset on Trulicity and how it can be used in a clinical setting,” David Kendall, Lilly’s VP of medical affairs, told FiercePharma at the meeting. “Even patients who’ve progressed to insulin therapy can still benefit” from the drug. The Trulicity-Lantus pair delivered A1C reductions of 1.44%, compared with 0.67% for Type 2 diabetes patients taking Lantus and a placebo. Plus, more than two-thirds of patients taking both drugs hit their A1C goal of less than 7%, while 35% of patients in the Lantus arm did. Fasting blood sugar dropped more in the combo arm, and after 28 weeks of treatment, patients taking Trulicity needed fewer units of Lantus to keep their glucose levels in check. Patients in the combo group also dropped weight--1.91 kg was the median measure--while those in the Lantus arm gained 0.5 kg. On the safety side, hypoglycemia rates were similar. About one-tenth of the Trulicity patients did experience nausea and/or diarrhea, consistent with previous studies of the drug. The Continue reading >>
- Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
- St. Luke’s Spotlights Critical Link Between Type 2 Diabetes and Heart Disease in Partnership with Boehringer Ingelheim and Eli Lilly and Company
- Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
Insulin Glargine First Line Vs Metformin In Type 2 Diabetic Subjects (glory)
Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit. After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose. Insulin glargine is given subcutaneously with an insulin-pen (SoloStar). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen. Continue reading >>
- Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls
- Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis
- Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis
Lantus And Metformin - Medhelp
Common Questions and Answers about Lantus and metformin thank you,i donot think she can,also will the lantus do more as it is increased and how far should the increase should it be done in 2u or can it go up 5u with no problems if i watch the blood sugars? Did you find the same thing if you are on metformin ER and /or Lantus ?Could it be that because I'm not evened out yet that my body is still making too much insulin and therefore my body is still holding on to fat? I'm confused, and I'm getting really frustrated that this is not kicking in faster.I am about to start a water aerobics class. I take Lantus and I also take Metformin 500 mg. twice a day. I am on 20 units of Lantus and have taken Lantus for years. (I use to be on 40 units a day, until I lost 125 pounds) I have not been good about following my diet and I notice that my blood sugar readings have been higher. My fasting blood sugars have been higher than normal (around 175) but I know it's because I have been eating too many carbs and have gained 20 pounds. I am currently using Lantus and Novolog. Drs. advice is to start with 40 units of Lantus and up it 2 units every third day until I get a fasting BG of less then 130. Is it more important to get to my Lantus goal on a consistant basis before I try to adjust my Novolog? My doctor's procedure is to stop taking Glucovance and to just be on Lantus , nothing else such as metformin . I am to keep increasing the Lantus until my levels are in the 180s. I am at 30 units of Lantus now, but my levels are all over the board depending on when I test. My doctor didn't say when to test and I think that would make a lot of difference. So, I am doing a fasting test in the morning and then test a few more times thru the day. Fasting levels are around 120 to 150. I am also on Continue reading >>
